Henlius Biotech gains approval for H share full circulation

Shanghai Henlius Biotech, Inc. (HKEX:2696) announced that the CSRC has accepted its filing application regarding the proposed implementation of H Share Full Circulation. This move will allow certain unlisted shares of the company to be converted into H shares, which will then be listed and traded on the Main Board of the Stock Exchange of Hong Kong. The company will release further announcements regarding the progress of the H Share Full Circulation and Conversion and Listing processes. Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.